NEWS

Zynerba Pharma announces top-line results from phase 2 star 1 trial of ZYN002

Tuesday, Aug 08, 2017

Zynerba Pharmaceuticals announces top-line results from phase 2 star 1 trial of ZYN002 in adult epilepsy patients with focal seizures.

Zynerba - ‍ZYN002 did not demonstrate a statistically significant reduction of focal seizures during treatment period.

Zynerba Pharmaceuticals Inc - ‍star 1 trial did not meet its primary endpoint?.

Zynerba Pharmaceuticals Inc - ‍will present top-line data from ZYN002 stop trial in osteoarthritis soon?.

Zynerba Pharmaceuticals Inc - ‍will present top-line data from Fab-C study in fragile X syndrome by end of September?.

Zynerba - ‍patients on low dose of ZYN002 achieved 18.4% median reduction in focal seizures during treatment period versus baseline?.

Zynerba Pharmaceuticals Inc - ‍none of secondary endpoints showed statistically significant differences between ZYN002 and placebo.

 

Source: reuters.com

Other News